CELU

Celularity Inc. Class A Common Stock (CELU) | Rumor.io

Celularity

CELU

Attention (50-day avg)0%

Attention rank (50-day avg)#871

Bullish sentiment (50-day avg)81%

Price to earnings ratio2.28

Market capitalization40.5M

Earnings per share-3.59

Dividend yield (TTM)—

Revenue (annual)26.6M

Net income (annual)-91.7M

Social

What share of all stock conversation is about CELU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 4

Celularity Inc. (CELU) missed its quarterly filing deadline and may face delisting from the Nasdaq.
The company's management has been criticized for lacking transparency, with some accusing them of hiding bad news, including a significant loss of $-37.76M equity and $-91.8M in the past quarter.
Despite concerns, some analysts believe that CELU's commercial traction, including a major US distribution deal, could lead to a turnaround, with short borrow rates and scarce share availability making holding a short position increasingly expensive.

Generated by AI

Sentiment

Of the messages about CELU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	71.43%	77.63% -3.2	79.72% +19.23
Bearish	—	28.57%	22.37% +3.2	20.28% -19.23

Bullish· Aug 31

*The company has been relatively heavy in buying, which could lead to a turning higher and a potential breakout to new highs.
*The new business strategy is beginning to take hold, with the CEO signing big contracts and significant catalysts coming in the near future.
*The company has a small market cap of $45M, but a new $300M deal could lead to a significant increase in value, potentially reaching the $5.00-$6.00 area.

Bearish· Aug 28

The stock has been rejected by selling walls, and each little pop has been met with a new wave of selling, dilution from convertible notes and potentially warrants is likely.
The company carries a high risk of insolvency or bankruptcy, having missed two 10-Q filings and potentially facing a delisting notice.
Shorts are likely to be squeezed as the stock is heavily shorted, and the market is already seeing signs of a short attack with aggressive selling and profit-taking.

Generated by AI

Topics

Of the messages about CELU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	53.85%	54.95%
Technical Analysis	—	0%	46.15%	39.41%
Analysts	—	0%	0%	1.13%
Controversies	—	0%	0%	1.13%
Earnings	—	0%	0%	1.13%
Macro	—	0%	0%	2.25%

Announcements· Aug 27

The company Celularity Inc. (CELU) has partnered with MuseCell Innovations to establish domestic production of Dezawa MuseCells at its facility in Florham Park, New Jersey.
The partnership is expected to generate over $300 million in cumulative purchase orders across five years, creating over 200 high-tech jobs at Celularity's facility.
The deal highlights Celularity's manufacturing capabilities and expertise in cellular medicine, with the potential to monetize its infrastructure through this partnership, rather than relying solely on its own drug-development pipeline.

Technical Analysis· Aug 27

The stock price of CELU has been increasing, with a day's high of $2.55 and 49 million shares exchanged, and it has performed well on higher-high breaks.
The stock has been rejected at $2.45, validating it as the key confirmation level for breakout inflow, and the author will remain patient and let the price action develop before taking action.
The author is watching for a $2.50 reclaim to signal another high break above $2.55, and a potential push into the $2.60s, with the stock's volatility remaining elevated.

Generated by AI

Community

Of the messages about CELU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	93.75%	24.64%	24.62%
Newcomers	0%	6.25%	75.36%	75.38%

Regulars· Aug 28

The regulars are optimistic about Celularity Inc. (CELU) after yesterday's corporate updates validated commercial interest in its platform, changing the dynamic for the company.
The insiders could have exercised their warrants if they wanted to, which could lead to a bigger push for the stock, and the regulars are expecting the price to continue upwards until compliance is regained.
The regulars are watching key price levels for CELU, including holding above $2.00, breaking $2.30 with heavy volume, and falling below $1.85, with a warning sign at $1.70-$1.75 and momentum structure weakening at $1.50.

Newcomers· Aug 31

Newcomers are focused on the potential for CELU to break through its recent high of $2.55 and continue to climb, with some expecting it to attack this level after hours.
The relatively low market cap of CELU ($45M) and its recent deal for $300M are seen as indicators of the stock's potential for significant growth, with some targets set at $5.00-$6.00.
Despite some concerns about the company's financial health and bankruptcy risk, many newcomers are optimistic about CELU's prospects, with some even expecting a 10% increase in value after hours.

Generated by AI

News

Celularity raises over $10M in debt financing, targets cash flow positive by Q1 2027

5d agoInvesting.com

Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements

5d agoYahoo Finance Singapore

Celularity regains Nasdaq compliance for bid price and market value

15d agoInvesting.com

Also Discussed

Investors talking about CELU also mention

#	Name	Attention
1	Banco Macro S.A. ADR Class BBMA	0%new
2	CECO Environmental Corp.CECO	0%0
3	Central Puerto SACEPU	0%new
4	Grupo Supervielle S.A.SUPV	0%0
5	Adecoagro S.A.AGRO	0%0
6	Grupo Financiero Galicia S.A. ADRGGAL	0.02%+0
7	Edenor S.A. ADREDN	0%-0.01
8	Loma Negra C.I.A.S.A. Sponsored ADRLOMA	0%new
9	IMV - IMV Inc.	——
10	YPF S.A. Sponsored ADRYPF	0%new

Celularity Inc. Class A Common Stock

Healthcare
Biotechnology

Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products. Celularity’s current business centers on three operating segments: Cell Therapy, Degenerative Disease, and BioBanking. The Cell Therapy segment develops off-the-shelf, cryopreserved allogeneic cell therapies, including programs based on mesenchymal-like adherent stromal cells, natural killer cells, and engineered T-cells for oncology, immune, infectious, and age-related diseases. The Degenerative Disease segment supports products used in surgical and wound care markets, while BioBanking provides storage services for stem cells from umbilical cords and placentas. Headquartered in Florham Park, New Jersey, Celularity occupies a niche within biotechnology that combines regenerative medicine research with commercial biobanking and biomaterials services.

Website

Location

170 Park Avenue

Florham Park, NJ, 07932

United States

Social

What share of all stock conversation is about CELU?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 4

Celularity Inc. (CELU) missed its quarterly filing deadline and may face delisting from the Nasdaq.
The company's management has been criticized for lacking transparency, with some accusing them of hiding bad news, including a significant loss of $-37.76M equity and $-91.8M in the past quarter.
Despite concerns, some analysts believe that CELU's commercial traction, including a major US distribution deal, could lead to a turnaround, with short borrow rates and scarce share availability making holding a short position increasingly expensive.

Generated by AI

Sentiment

Of the messages about CELU that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	71.43%	77.63% -3.2	79.72% +19.23
Bearish	—	28.57%	22.37% +3.2	20.28% -19.23

Bullish· Aug 31

*The company has been relatively heavy in buying, which could lead to a turning higher and a potential breakout to new highs.
*The new business strategy is beginning to take hold, with the CEO signing big contracts and significant catalysts coming in the near future.
*The company has a small market cap of $45M, but a new $300M deal could lead to a significant increase in value, potentially reaching the $5.00-$6.00 area.

Bearish· Aug 28

The stock has been rejected by selling walls, and each little pop has been met with a new wave of selling, dilution from convertible notes and potentially warrants is likely.
The company carries a high risk of insolvency or bankruptcy, having missed two 10-Q filings and potentially facing a delisting notice.
Shorts are likely to be squeezed as the stock is heavily shorted, and the market is already seeing signs of a short attack with aggressive selling and profit-taking.

Generated by AI

Topics

Of the messages about CELU that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	53.85%	54.95%
Technical Analysis	—	0%	46.15%	39.41%
Analysts	—	0%	0%	1.13%
Controversies	—	0%	0%	1.13%
Earnings	—	0%	0%	1.13%
Macro	—	0%	0%	2.25%

Announcements· Aug 27

The company Celularity Inc. (CELU) has partnered with MuseCell Innovations to establish domestic production of Dezawa MuseCells at its facility in Florham Park, New Jersey.
The partnership is expected to generate over $300 million in cumulative purchase orders across five years, creating over 200 high-tech jobs at Celularity's facility.
The deal highlights Celularity's manufacturing capabilities and expertise in cellular medicine, with the potential to monetize its infrastructure through this partnership, rather than relying solely on its own drug-development pipeline.

Technical Analysis· Aug 27

The stock price of CELU has been increasing, with a day's high of $2.55 and 49 million shares exchanged, and it has performed well on higher-high breaks.
The stock has been rejected at $2.45, validating it as the key confirmation level for breakout inflow, and the author will remain patient and let the price action develop before taking action.
The author is watching for a $2.50 reclaim to signal another high break above $2.55, and a potential push into the $2.60s, with the stock's volatility remaining elevated.

Generated by AI

Community

Of the messages about CELU, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	93.75%	24.64%	24.62%
Newcomers	0%	6.25%	75.36%	75.38%

Regulars· Aug 28

The regulars are optimistic about Celularity Inc. (CELU) after yesterday's corporate updates validated commercial interest in its platform, changing the dynamic for the company.
The insiders could have exercised their warrants if they wanted to, which could lead to a bigger push for the stock, and the regulars are expecting the price to continue upwards until compliance is regained.
The regulars are watching key price levels for CELU, including holding above $2.00, breaking $2.30 with heavy volume, and falling below $1.85, with a warning sign at $1.70-$1.75 and momentum structure weakening at $1.50.

Newcomers· Aug 31

Newcomers are focused on the potential for CELU to break through its recent high of $2.55 and continue to climb, with some expecting it to attack this level after hours.
The relatively low market cap of CELU ($45M) and its recent deal for $300M are seen as indicators of the stock's potential for significant growth, with some targets set at $5.00-$6.00.
Despite some concerns about the company's financial health and bankruptcy risk, many newcomers are optimistic about CELU's prospects, with some even expecting a 10% increase in value after hours.

Generated by AI

Celularity

Social

Sep 4

Bullish· Aug 31

Bearish· Aug 28

Announcements· Aug 27

Technical Analysis· Aug 27

Regulars· Aug 28

Newcomers· Aug 31

Celularity adds Viome CEO Naveen Jain to board of directors

Celularity Announces Naveen Jain to Join Board of Directors

Celularity announces $25 million convertible note financing and board changes

Celularity raises over $10M in debt financing, targets cash flow positive by Q1 2027

Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements

Celularity regains Nasdaq compliance for bid price and market value

Also Discussed

Celularity Inc. Class A Common Stock

Company Information

Location

Celularity adds Viome CEO Naveen Jain to board of directors

Celularity Announces Naveen Jain to Join Board of Directors

Celularity announces $25 million convertible note financing and board changes

Celularity raises over $10M in debt financing, targets cash flow positive by Q1 2027

Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements

Celularity regains Nasdaq compliance for bid price and market value

Also Discussed

Social

Sep 4

Bullish· Aug 31

Bearish· Aug 28

Announcements· Aug 27

Technical Analysis· Aug 27

Regulars· Aug 28

Newcomers· Aug 31